Biotech Values

[mcbio]

Re: MNTA/four arguments re Copaxone patent case

• As reported in the public court pleadings, NVS/MNTA intend to pursue four arguments: i) indefiniteness of Teva’s patents; ii) invalidity of Teva’s patents due to obviousness and/or double patenting; ii) non-infringement by NVS/MNTA’s product; and iv) inequitable conduct.

I assume MNTA need only succeed on one of these four arguments. Is that correct? Also, which of the four arguments do you see as holding the best chance for MNTA to succeed?